ImmunoForge Co., Ltd. aims to establish strategic partnerships at Bio-Europe Spring 2026, showcasing their innovative biopharmaceutical technologies and therapies.

ImmunoForge will hold strategic meetings with pharmaceutical companies during the 2026 J.P. Morgan Healthcare Conference to advance its innovative treatments.

🔊Autolus Therapeutics Secures FDA Approval for Aucatzyl Cell Therapy in Relapsed B-Cell Leukemia Autolus Therapeutics is launching Aucatzyl commercially in the U.S.

The South Korean biotech firm ImmunoForge has been chosen for a key government program aimed at enhancing advancements in technology for rare diseases.

Development of Leptin receptor-based technology and hybrid LNP platform Combining Blood-Brain Barrier penetration and a one-month sustained-release formulation in a single structure, with potential applications in CNS-targeted therapeutics Technology validated by winning first place in...

Conducting global licensing partnering of LMT15, a proprietary BBB Shuttle platform Also discussing global out-licensing of Phase 2 stage new drugs PF1801 and PF1804 SEOUL, South Korea, March 12, 2026 /PRNewswire/ — ImmunoForge Co., Ltd., a biopharmaceutical company developing treatments for rare diseases, announced that they will participate in Bio-Europe Spring 2026, held in Lisbon, […]

The Key Sarcopenia Companies in the market inlcude- TNF Pharmaceuticals, Lipocine, Biophytis, ImmunoForge, Rejuvenate Biomed, Keros Therapeutics, BPGbio, Oncocross, Mirscience Therapeutics, Turn Biotechnologies, NMD PHARMA, ImmunoForge, Dong Wha PHARM, and others.   DelveInsight’s “Sarcopenia Market Insights, Epidemiology, and Market Forecast-2034″ … Continue reading →

ImmunoForge Co., Ltd unravels the LMT15 platform, set to revolutionize CNS drug development through enhanced blood-brain barrier permeability.

ImmunoForge has secured IND approvals for Phase 2 trial of Pemziviptadil for DMD cardiomyopathy and Phase 1 trial for KF1601 targeting leukemia, marking critical progress.

ImmunoForge's LMT15 Platform combines high BBB permeability with proprietary long-acting ELP technology Technology excellence validated by winning first place at 'Novo Nordisk Partnering Day Korea 2026' SEOUL, South Korea, April 22, 2026 /PRNewswire/ -- ImmunoForge Co., Ltd., a...

Focusing on global out-licensing of Phase 2 assets PF1801 and PF1804. Company to engage with global big pharma in San Francisco to accelerate U.S. clinical entry. SEOUL, South Korea, Jan. 1, 2026 /PRNewswire/ -- ImmunoForge Co., Ltd. (Co-CEOs Sung-Min Ahn and Kiho Chang), a clinical-stage...

SEOUL, South Korea, Jan. 14, 2025 /PRNewswire/ -- ImmunoForge announced that it has received approval for the Phase 2 clinical trial IND for 'Pemziviptadil (development code name PF1804),' a treatment for DMD (Duchenne Muscular Dystrophy) cardiomyopathy,…

ImmunoForge, a pioneering biotech company, is making significant strides in the treatment of serious medical conditions with the recent approval of two Investigational New Drug (IND) applications by r...